Open AccessCarvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway
Author(s) -
Qian Ding,
Xiangguo Tian,
Yan Li,
Qizhi Wang,
Chunqing Zhang
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i32.9566
Subject(s) - carvedilol , angiogenesis , mapk/erk pathway , proto oncogene tyrosine protein kinase src , pharmacology , vascular endothelial growth factor , signal transduction , chemistry , kinase , cell growth , microbiology and biotechnology , endocrinology , medicine , cancer research , biology , biochemistry , heart failure , vegf receptors
To investigate the effect of carvedilol on angiogenesis and the underlying signaling pathways.